41 results about "FLT3 Inhibitor" patented technology

The invention relates to a pteridinone derivative used as an FLT3 inhibitor, and an application thereof, and concretely relates to a compound represented by formula I, a medicinal composition containing the compound of formula I, and a use of the compound in the preparation of medicines for treating FLT3 mediated diseases or inhibiting the FLT3.

The invention relates to pteridinone derivatives as FLT3 inhibitors and a use thereof. The invention relates to a compound shown in the formula I, a pharmaceutical composition containing the compound shown in the formula I and a use of the compound in preparation of drugs for treating FLT3-mediated diseases or inhibiting FLT3.

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

The invention refers to an FLT3 inhibitors for immune suppression. New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.

Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

Inventors have evaluated the effects of the FLT3 inhibitors on morphine analgesic potency, on tolerance to morphine analgesia and on morphine-induced mechanical pain hypersensitivity. When the FLT3 inhibitor was administered together with morphine, the amount of analgesic effect was higher than that produced by morphine alone. Repeated administration of morphine induced a progressive decrease in morphine-induced analgesia as showed by the decreased percentage of MPE in control animals. Intrathecal pre-treatment with an FLT3 inhibitor reduced the decrease in morphine analgesia. The administration of FLT3 inhibitors completely prevented both the development of morphine-induced pain hypersensitivity and morphine-revealed latent pain sensitization. Accordingly, the invention relates to an FLT3inhibitor for increasing the efficacy of an opioid for its analgesic effect, and hereby reducing the opioid dose while maintaining the opioid efficacy in a subject suffering from pain in need thereof.

The invention relates to a novel 4-(aromatic heterocyclic substituted)amino-1H-3-pyrazolecarboxamide compound or pharmaceutically acceptable salts, solvates, isomers, esters, acids, metabolites or pro-drugs thereof and a preparation method thereof. The invention provides medical compositions comprising the compounds and medical application thereof.

The present invention relates to a pteridinone derivative serving as an FLT3 inhibitor, and uses thereof. Specifically, the present invention relates to a compound represented by formula (I), a pharmaceutical composition containing the compound represented by formula (I), and uses of the compound in the preparation of drugs for treating diseases mediated by FLT3 or for inhibiting the FLT3: (I).